Silence Therapeutics at Cantor healthcare conference: divesiran advances
Silence Therapeutics (SLN) presented updates on its lead drug, divesiran, at the Cantor Fitzgerald Global Healthcare Conference. Phase II data showed strong response rates in polycythemia vera, with 90% at 6 mg every 6 weeks and 88% at 6 mg every 12 weeks. The company raised $200 million, ending Q2 with $72 million in cash, providing a 2.5-3 year runway. Management is preparing for Phase III discussions and weighing partnership options amid rising competition. SLN also highlighted other pipeline
How this was made
The 30-second read
Why it matters
The disclosed Phase II efficacy and safety data provide a material catalyst that could drive near‑term price movement and influence valuation models.
Market read
First‑time detailed Phase II results for a late‑stage RNA therapeutic, a high‑impact event for biotech investors.
What to watch
Competition from rusfertide and other siRNA programs may limit market share; cash runway constraints could pressure financing needs.
Background
Silence Therapeutics used the Cantor Healthcare Conference to update investors on its lead program divesiran and other pipeline assets.
Ticker impact
Silence Therapeutics presented Phase II data for its lead siRNA drug divesiran, reporting ~90% response rates in polycythemia vera patients.
Potential upside of 15‑25% if Phase III design is approved and data remain strong.
Phase II data are the first detailed efficacy readout; investors typically reward biotech stocks on strong early‑stage results, especially with a clear path to Phase III.
Market effects
Strengthens the broader siRNA and rare‑blood‑disorder therapeutic sector, potentially lifting peers like Alnylam (ALNY) and Arrowhead (ARWR).
Positive for UK‑listed biotech exposure and may boost European biotech ETFs.
Adds to global momentum for RNA‑based medicines, supporting continued investor interest in the space.
Counterpoint
If Phase III design proves costly or regulatory hurdles arise, the stock could face a steep correction despite Phase II success.
Key entities
- companySilence Therapeutics
UK‑based biotech developing siRNA therapeutics, ticker SLN.
- drugDivesiran
Lead siRNA candidate targeting TMPRSS6 for polycythemia vera.
